Last reviewed · How we verify
Sulfadoxine-pyrimethamine used for IPTi
Sulfadoxine-pyrimethamine used for IPTi is a Antifolate antimalarial combination Small molecule drug developed by Swiss Tropical & Public Health Institute. It is currently in Phase 3 development for Intermittent preventive treatment of malaria in infants (IPTi), Malaria treatment and prophylaxis. Also known as: Brand of SP used is Fanisdar.
Sulfadoxine-pyrimethamine is a fixed-dose combination of two antifolate drugs that inhibits dihydrofolate reductase and dihydropteroate synthase, blocking folate synthesis in malaria parasites.
Sulfadoxine-pyrimethamine is a fixed-dose combination of two antifolate drugs that inhibits dihydrofolate reductase and dihydropteroate synthase, blocking folate synthesis in malaria parasites. Used for Intermittent preventive treatment of malaria in infants (IPTi), Malaria treatment and prophylaxis.
At a glance
| Generic name | Sulfadoxine-pyrimethamine used for IPTi |
|---|---|
| Also known as | Brand of SP used is Fanisdar |
| Sponsor | Swiss Tropical & Public Health Institute |
| Drug class | Antifolate antimalarial combination |
| Target | Dihydropteroate synthase; Dihydrofolate reductase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Sulfadoxine inhibits dihydropteroate synthase, while pyrimethamine inhibits dihydrofolate reductase, both enzymes critical for parasitic folate metabolism. This dual mechanism prevents DNA synthesis in Plasmodium parasites. When used for intermittent preventive treatment in infants (IPTi), it provides prophylactic protection against malaria in high-transmission settings.
Approved indications
- Intermittent preventive treatment of malaria in infants (IPTi)
- Malaria treatment and prophylaxis
Common side effects
- Rash
- Gastrointestinal disturbances
- Folate deficiency
- Stevens-Johnson syndrome (rare)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sulfadoxine-pyrimethamine used for IPTi CI brief — competitive landscape report
- Sulfadoxine-pyrimethamine used for IPTi updates RSS · CI watch RSS
- Swiss Tropical & Public Health Institute portfolio CI
Frequently asked questions about Sulfadoxine-pyrimethamine used for IPTi
What is Sulfadoxine-pyrimethamine used for IPTi?
How does Sulfadoxine-pyrimethamine used for IPTi work?
What is Sulfadoxine-pyrimethamine used for IPTi used for?
Who makes Sulfadoxine-pyrimethamine used for IPTi?
Is Sulfadoxine-pyrimethamine used for IPTi also known as anything else?
What drug class is Sulfadoxine-pyrimethamine used for IPTi in?
What development phase is Sulfadoxine-pyrimethamine used for IPTi in?
What are the side effects of Sulfadoxine-pyrimethamine used for IPTi?
What does Sulfadoxine-pyrimethamine used for IPTi target?
Related
- Drug class: All Antifolate antimalarial combination drugs
- Target: All drugs targeting Dihydropteroate synthase; Dihydrofolate reductase
- Manufacturer: Swiss Tropical & Public Health Institute — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Intermittent preventive treatment of malaria in infants (IPTi)
- Indication: Drugs for Malaria treatment and prophylaxis
- Also known as: Brand of SP used is Fanisdar
- Compare: Sulfadoxine-pyrimethamine used for IPTi vs similar drugs
- Pricing: Sulfadoxine-pyrimethamine used for IPTi cost, discount & access